Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING: University hospital. PARTICIPANTS: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. INTERVENTION: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. RESULTS: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). LIMITATION: Single-center study. CONCLUSION: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. PRIMARY FUNDING SOURCE: Burroughs Wellcome Fund and American Diabetes Association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefi cial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been seen with pioglitazone (200,201).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“weight gain was also significantly higher in the treatment group [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“a randomized controlled trial including 101 patients with either pre‐ or type 2 diabetes found that 51% in the Pioglitazone group (45 mg/day) had resolution of NASH and 58% achieved the primary outcome of the study (reduction of ≥2 NAS points in two histologic categories without worsening of fibrosis), both significantly [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“Pioglitazone treatment was also associated with a significant improvement in fibrosis score.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“5) mg/dL 149 (36) 153 (34) 1 (−18 to 19) LDL cholesterol level 0.”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 3×
“Additional secondary outcomes included the following: 1) fasting plasma glucose, fasting plasma insulin, FFA, hemoglobin A1c, fasting plasma lipid profile, adiponectin, and cytokeratin-18 concentrations; 2) total body fat percentage, measured by DXA; 3) hepatic triglyceride content, measured by magnetic resonance and…”
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“001 Fibrosis ≥1-point improvement, n (%) 13 (25) 20 (39) 14 (−6 to 34) 0.”
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Research works printed but not linked: 1
- Bril F, 2015, Diabetes, 64, A337
Cited by
Items 701–800 of 1,001
Nonalcoholic Fatty Liver Disease
Argo, C. K., Henry, Z. H., & Caldwell, S. H. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch32 · Cited by 7
Chen, X., Chu, F., Sunchen, S., Li, J., Zhang, M., Xu, F., & Dong, H. F. (2024) · The Journal of Physiology · doi:10.1113/jp287092 · Cited by 6
Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2025.502442 · Cited by 9
Pi, S., Zhang, S., Zhang, J., Guo, Y., Li, Y., Deng, J., & Du, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1626352 · Cited by 190
PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100590 · Cited by 7
Fouad, Y., Elwakil, R., Sanai, F. M., Ojo, O. S., Awadhi, S. A., Ocama, P., Abdelkader, N. A., Al‐Busafi, S. A., Awuku, Y. A., Zaki, S., et al. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102180 · Cited by 10
New Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 12
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
Self-citationAkuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02408-2 · Cited by 10
Current Treatment Options, Including Diet, Exercise, and Medications
Noureddin, M., & Abdelmalek, M. F. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.008 · Cited by 7
Tanabe, K. K., Zahrieh, D. M., Strand, C. A., Hoshida, Y., Flotte, T. J., Della’Zanna, G., Umar, A., Chavin, K. D., Cleary, S. P., Kubota, N., et al. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.01.009 · Cited by 9
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
Lee, H. A., Lee, H. A., & Kim, H. Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-79428-6 · Cited by 7
de Souza, M. H. G., Amaral, M. J. M., Lima, L. C. V., & Villela‐Nogueira, C. A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18498 · Cited by 6
Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease
Cai, C. X., Carlos, S., Solaimani, P., Trivedi, B. J., Tran, C. T., & Castelino‐Prabhu, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00029-x · Cited by 6
Evolving Concepts of Type 2 Diabetes Management
Abushamat, L. A., & Reusch, J. E. B. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.003 · Cited by 7
Nonalcoholic Fatty Liver Disease
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_9 · Cited by 6
Zhang, F., Ji, L., Hong, T., Guo, L., Li, Y., Zhu, Z., Liu, X., Liu, F., Tang, L., Zhang, Y., et al. (2022) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12474 · Cited by 8
Can pioglitazone be used for optimization of nutrition in critical illness? A systematic review
McClelland, T. J., Fowler, A. J., Davies, T., Pearse, R. M., Prowle, J. R., & Puthucheary, Z. (2023) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2481 · Cited by 6
Jung, C., Park, S., & Kim, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294423 · Cited by 6
Iruarrizaga‐Lejarreta, M., Bril, F., Noureddin, M., Ortiz, P., Lu, S. C.-L., Mato, J. M., & Alonso, C. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_16 · Cited by 9
Self-citationUpdate on cardiovascular risk in nonalcoholic fatty liver disease
Johnston, M. P., Patel, J., & Byrne, C. D. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000861 · Cited by 6
“) It is clear that pioglitazone benefits liver disease in NASH in patients both with, and without T2DM [44,48].”
BackgroundNon-alcoholic Fatty Liver Disease: A Global Public Health Issue
Kaya, E., & Yilmaz, Y. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_24 · Cited by 10
Reply to “statins and non-alcoholic steatohepatitis”
Barb, D., & Cusi, K. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.10.004 · Cited by 7
Self-citationKhan, R. S., & Newsome, P. N. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05573-y · Cited by 6
Seshadri, K., PADHYE, D. A., Tippisetty, S., Polisetti, S., & Gadia, S. (2024) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071241281419 · Cited by 5
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
“Pioglitazone was the first TZD used in an RCT to effectively reverse MASH activity (steatosis and inflammation) [282] without a clear effect on fibrosis [293].”
Koullias, E., Papavdi, M., Koskinas, J. S., Deutsch, M. J., & Thanopoulou, A. C. (2025) · Cureus · doi:10.7759/cureus.76716 · Cited by 13
Non-alcoholic fatty liver disease: modern approaches to diagnosis and treatment
Канорский, С. Г. (2021) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2021-2-3-18-29 · Cited by 7
Asakawa, M., Takagi, N., Hamada, D., Yamasaki, Y., & Katsuta, H. (2023) · Diabetology International · doi:10.1007/s13340-023-00619-z · Cited by 6
Zeng, M., Chen, L., Li, Y., Mi, Y., & Xu, L. (2023) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000085 · Cited by 5
A continuous-time Markov chain model of fibrosis progression in NAFLD and NASH
Meyer, L. F., Musante, C. J., & Allen, R. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1130890 · Cited by 6
“data after 18 months [Appendix (21)] with just α parameters, which are the fold changes for forward parameters.”
MethodInfluentialMcCall, K. D., Walter, D. L., Patton, A., Thuma, J. R., Courreges, M. C., Palczewski, G., Goetz, D. J., Bergmeier, S. C., & Schwartz, F. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s413565 · Cited by 5
Sogabe, M., Okahisa, T., Kagawa, M., Kashihara, T., Shinomiya, R., Miyake, T., Kawaguchi, T., Yokoyama, R., Kagemoto, K., Kida, Y., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18280 · Cited by 5
Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database
Du, H., Huang, J., Wang, Y., Wang, C., Wang, Y., Hou, L., Li, Y., Li, Y., & Su, Q. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03732-2 · Cited by 7
Pioglitazone safe and effective for treating T2DM in patients with NASH
Geach, T. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.113 · Cited by 5
Basic Concepts in Insulin Resistance and Diabetes Treatment
Bril, F., & Cusi, K. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-72475-1_3 · Cited by 5
Self-citationEffectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis
Huang, Y., Yang, G., Wang, C., Chen, X., & Zhang, L. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i9.1576 · Cited by 6
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Grzych, G., Bernard, L., Lestrelin, R., Tailleux, A., & Staels, B. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.09.005 · Cited by 6
Pioglitazone and cardiovascular risk reduction: time for a second look?
Perdigoto, A. L., Young, L. H., & Inzucchi, S. E. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000110 · Cited by 5
Clinical workup of fatty liver for the primary care provider
Jensen, T., Wieland, A. C., Cree‐Green, M., Nadeau, K. J., & Sullivan, S. A. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2019.1546532 · Cited by 5
Nonalcoholic Fatty Liver Disease
Haddad, N. N., Singh, A., Malakouti, M., & Alkhouri, N. (2018) · Springer eBooks · doi:10.1007/978-3-319-98506-0_8 · Cited by 5
Case of lipoatrophic diabetes induced by juvenile dermatomyositis
Baba, Y., Kaneko, H., Takemoto, M., Ide, K., Haga, Y., Kanda, T., Akita, S., Kubota, Y., Kuroda, M., Kitagawa, Y., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12745 · Cited by 5
Pieralice, S., Amendolara, R., Berna, V., Manganaro, G., Zurru, A., D’Onofrio, L., Risi, R., Alfonsi, M., Maddaloni, E., & Buzzetti, R. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s528569 · Cited by 10
Kumar, A. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1058 · Cited by 7
Alcohol-Related Liver Disease: A Review
Krag, A. A., Åberg, F., Mellinger, J. L., Lee, B. P., & Israelsen, M. E. (2026) · JAMA · doi:10.1001/jama.2026.12038 · Cited by 9
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 7
Malandris, K., Papandreou, S., Vasilakou, D., Kakotrichi, P., Sarakapina, A., Kalopitas, G., Karagiannis, T., Γιουλεμέ, Ό., Bekiari, E., Liakos, A., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16559 · Cited by 5
“Se-maglutide Se-maglutide was ranked as the most ef fi cacious treatment (0.97) being superior to most active interventions including dulaglutide, efruxifermin, pegozafermin, cilofexor, and obeticholic acid (Tables S32,33).”
InfluentialUnraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives
Yadav, M. C., Verma, S., Tiwari, P., & Mugale, M. N. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122934 · Cited by 5
Abdul‐Ghani, M. A., PUCKETT, C. L., Abdelgani, S., Merovci, A., Lavrynenko, O., Adams, J. M., Triplitt, C. L., & DeFronzo, R. A. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-004981 · Cited by 6
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
Shenoy, A., Ahmed, A., & Kim, D. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.73 · Cited by 10
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
BAJAJ, H. S., & Zinman, B. (2018) · Physiology · doi:10.1152/physiol.00004.2018 · Cited by 7
“Thiazolidinediones, such as pioglitazone, have, to date, been the only class of AHAs to demonstrate beneficial hepatic effects in two separate, albeit small, randomized control trials (11, 27) and are hence recommended in NAFLD guidelines, along with lifestyle modifications (17).”
BackgroundPerspective strategies for non-alcoholic fatty liver disease therapy: from trial to practice
Бакулин, И. Г., Belousova, L. N., Li, N., & Sushilova, A. G. (2020) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-170-10-18-25 · Cited by 4
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Valle-Velázquez, E., Cabrera-Angeles, J. C., Sánchez-Gloria, J. L., Sánchez‐Muñoz, F., Arellano-Buendía, A. S., Sánchez‐Lozada, L. G., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123638 · Cited by 7
Rajan, V., Das, A., Jayaseelan, V., Lohani, K. K., & Lahariya, C. (2025) · Preventive Medicine Research & Reviews · doi:10.4103/pmrr.pmrr_159_24 · Cited by 5
HIV-Associated NAFLD: Disease Burden and Management
Kaplan, A. J., & Price, J. C. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00501-0 · Cited by 5
Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
Hartl, L., Elias, J., Prager, G., Reiberger, T., & Unger, L. W. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i19.2281 · Cited by 4
Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development
Kemas, A. M., Youhanna, S. C., & Lauschke, V. M. (2022) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2022.2053285 · Cited by 5
Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
Cho, Y. E., Kwon, Y. S., & Hwang, S. (2022) · Liver Research · doi:10.1016/j.livres.2022.06.001 · Cited by 7
“133 In a phase III trial (NCT00063622), combined pioglitazone and vitamin E ameliorated fatty liver and lobular in fl ammation in patients with NASH but failed to improve fi brosis.”
Pioglitazone-Enhanced Brown Fat Whitening Contributes to Weight Gain in Diet-Induced Obese Mice
Yu, P., Wang, W. J., Guo, W., Cheng, L., Wan, Z., Cheng, Y., Shen, Y., & Xu, F. L. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2178-9113 · Cited by 6
Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review
Demidova, T. Y., & Омариевна, У. Ф. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.10.202435 · Cited by 5
Davison, B. A., Edwards, C., Loomba, R. S., Harrison, S. A., Cotter, G., Alkhouri, N., Koch, G. G., & Dittrich, H. C. (2021) · JGH Open · doi:10.1002/jgh3.12575 · Cited by 4
Non-alcoholic Fatty Liver Disease
Kim, S. F., & Choi, J. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_36 · Cited by 4
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis
Thomas, J. A., Gupta, R., & Aithal, G. P. (2017) · Annals of Internal Medicine · doi:10.7326/l16-0628 · Cited by 4
Management of Nonalcoholic Fatty Liver Disease (NAFLD)
Ahmed∥, M. (2018) · InTech eBooks · doi:10.5772/intechopen.72000 · Cited by 4
Francque, S. (2021) · Hepatology · doi:10.1002/hep.32024 · Cited by 6
Jayabalan, D., Dhakal, S., Chandra, J., Fasser, D. A., Jeffrey, G. P., Garas, G., Vilar-Gomez, E., Calzadilla-Bertot, L., & Adams, L. A. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003918 · Cited by 3
Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
Brennan, P. N., The University of Edinburgh, C. F. R. M., NHS Tayside, N. H. A. M. S., The University of Dundee, D. O. M. A. C. M., Dillon, J. F., NHS Tayside, N. H. A. M. S., The University of Dundee, D. O. M. A. C. M., McCrimmon, R., NHS Tayside, N. H. A. M. S., & The University of Dundee, D. O. M. A. C. M. (2022) · European Endocrinology · doi:10.17925/ee.2022.18.2.148 · Cited by 3
7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112151 · Cited by 3
Liang, Z., Chen, L., Liao, Z., Mao, J., Liu, Y., & Li, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01825 · Cited by 3
Xiao, Z., Li, X., Gong, J., & Zhou, F. (2025) · European journal of medical research · doi:10.1186/s40001-025-03445-y · Cited by 3
Zacharia, G. S., Ashraf, M. H., Sosa, F., Jacob, A., & Patel, H. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.110827 · Cited by 3
Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions
Qu, J., Qin, W., Dong, M., Ma, Z., Li, S., Liu, R., Chen, R., Li, C. H., & Li, X. (2026) · MedComm · doi:10.1002/mco2.70750 · Cited by 4
Bano, S., Copeland, M. A., Liu, J.-J., Orr, A. V., Stoops, J. W., Mars, W. M., Liu, S., Locker, J. D., Michalopoulos, G. K., & Bhushan, B. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.04.015 · Cited by 4
Tang, M., Ma, Y., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829315 · Cited by 3
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
How far are we from an approved drug for nonalcoholic steatohepatitis?
Méndez‐Sánchez, N., Pal, S. C., & Córdova‐Gallardo, J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206953 · Cited by 3
Yap, C. H., Junit, S. M., Aziz, A. A., Leong, K. H., Hwong, C. S., & Kong, K. W. (2023) · South African Journal of Botany · doi:10.1016/j.sajb.2023.07.055 · Cited by 3
Kitsios, K., Trakatelli, C., Antza, C., Triantafyllou, Α., Sarigianni, M., & Kotsis, V. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0059 · Cited by 3
Wang, X.-Y., Lyu, Q., Zhang, Y., Su, Y., Zhao, H., Shen, H., & Xie, Y. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.129 · Cited by 4
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 4
“Histologic improvements in steatosis (71% vs. 26%, p < 0.001), inflammation (49% vs. 22%; p = 0.004), and ballooning (51% vs. 24%; p = 0.004) were observed, though fibrosis improvement was modest ( p = 0.039) [36].”
InfluentialLu, Y., Oshins, R. A., Maptue, N. R., Shen, Q., Khemtong, C., Cusi, K. J., Brantly, M., & Khodayari, N. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00272.2025 · Cited by 3
Self-citationCroatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease
Jukić, L. V., Grgurević, I., Mikolašević, I., Kanižaj, T. F., Milić, S., Mrzljak, A., Premužić, M., Hrstić, I., Knežević-Štromar, I., Ljubičić, N., et al. (2021) · Acta Clinica Croatica · doi:10.20471/acc.2021.60.s1.03 · Cited by 4
As, A., P'yanykh, O. P., & Vovk, P. S. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-2-56-63 · Cited by 4
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség. II. Kezelés
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32480 · Cited by 3
Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment
Arredouani, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106445 · Cited by 4
Xie, Q., Pan, X., Zhang, X., Ma, J., Peng, G., & Tong, N. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002778 · Cited by 3
“Cusi et al [5] published the results of an RCT of the use of pioglitazone in patients with NAFLD and T2D or prediabetes in 2016.”
Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions
Choudhuri, G., Shah, S., Kulkarni, A. V., Jagtap, N., Gaonkar, P. P., Desai, A. S., & Adhav, C. V. (2023) · Cureus · doi:10.7759/cureus.42852 · Cited by 4
“%) is much higher in patients with type 2 diabetes mellitus (T2DM) [22].”
BackgroundInfluentialKostitska, I. O., Protas, N., & Petrovska, L. (2023) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2023-5-01 · Cited by 3
Alexopoulos, A., Parish, A., Olsen, M. K., Batch, B. C., Moylan, C. A., & Crowley, M. J. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003763 · Cited by 3
Indian Literature Review on Nonalcoholic Fatty Liver Disease
Balamurali, R., Murugesan, M., Shanmugam, C., Gopalsamy, S., & Chinnadurai, K. K. (2023) · Gastroenterology Hepatology and Endoscopy Practice · doi:10.4103/ghep.ghep_23_23 · Cited by 3
Conroy, C., Radulescu, A., Attia, S. L., Shelman, N. R., Lee, J. T., Galuppo, R., Hall, S., Kohli, R., & Softic, S. (2024) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_428_23 · Cited by 7
“[23,24] In spite of its perceived efficacy, pioglitazone is not widely used for management of adult patients with MASLD, likely due to its side effect profile.”
BackgroundHígado graso no alcohólico y diabetes
Reyes‐García, R., Rozas-Moreno, P., Llamoza-Torres, C. J., & Mezquita‐Raya, P. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.08.005 · Cited by 4
Welches (ist das richtige) Target bei nichtalkoholischer Fettleber (NAFLD)
Huber, Y., Galle, P. R., & Schattenberg, J. M. (2020) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1068-3981 · Cited by 5
Current and Emerging Treatments for Non-alcoholic Steatohepatitis
Horn, C. L., Ta, A. C., & Gunn, N. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00540-y · Cited by 3
Ghosh, S., Khatoon, R., Sarkar, S., & Bandyopadhyay, D. (2023) · Melatonin Research · doi:10.32794/mr112500138 · Cited by 3
Bril, F., Kalavalapalli, S., Lomonaco, R., & Cusi, K. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14936 · Cited by 4
Self-citationNon‐alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control
Bloomgarden, Z. T. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12566 · Cited by 3
Durairajan, S. S. K., Singh, A. K., & Iyaswamy, A. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i35.3965 · Cited by 5
Targher, G., Mantovani, A., & Bonora, E. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_17 · Cited by 2
Metadata
- Authors
- Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., Webb, A., & Portillo-Sanchez, P.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- From University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida, and University of Texas Health Science Center at San Antonio and Audie L. Murphy Veterans Affairs Medical Center, San Antonio, Texas.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-09-06
- Volume
- 165
- Issue
- 5
- Pages
- 305-315
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2470709274
- Cited by
- 1,024
- References
- 62
- Citations by year
- 2026: 82 · 2025: 108 · 2024: 109 · 2023: 103 · 2022: 116 · 2021: 131 · 2020: 108 · 2019: 85 · 2018: 85 · 2017: 67 · 2016: 27
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- U.S. Department of Veterans Affairs (1 I01 CX000167-01)
- American Diabetes Association
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, nonalcoholic steatohepatitis, prediabetes, type 2 diabetes, long-term treatment, hypocaloric diet, NASH resolution, liver fibrosis, hepatic triglyceride content, insulin sensitivity, insulin resistance, PPARγ agonists, drug safety, adverse events, liver histopathology, hepatic steatosis
- MeSH terms
- Pioglitazone, Transaminases, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Prediabetic State, Triglycerides, Biomarkers, Weight Gain, Thiazolidinediones, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.